menu
    • menu
    [{"orgOrder":0,"company":"DermaGen","sponsor":"Pergamum","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"DPK-060","moa":"\nCell membrane permeability","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"DermaGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DermaGen \/ Pergamum","highestDevelopmentStatusID":"8","companyTruncated":"DermaGen \/ Pergamum"},{"orgOrder":0,"company":"Simbec Research","sponsor":"Sensorion","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Simbec Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Simbec Research \/ Sensorion","highestDevelopmentStatusID":"6","companyTruncated":"Simbec Research \/ Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Association for Research in Otolaryngology","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Association for Research in Otolaryngology"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Cochlear Limited","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Cochlear Limited"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"CYR-064","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"STS Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"STS Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"STS Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"STS Medical \/ Undisclosed"},{"orgOrder":0,"company":"Andrew Chung","sponsor":"More Foundation | Banner Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Andrew Chung","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Andrew Chung \/ More Foundation | Banner Health","highestDevelopmentStatusID":"1","companyTruncated":"Andrew Chung \/ More Foundation | Banner Health"},{"orgOrder":0,"company":"McNeil AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Xylometazoline","moa":"Adrenergic receptor alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"McNeil AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"McNeil AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"McNeil AB \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Avanz Cupressus Arizonica","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Avanz Phleum Pratense","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Avanz Phleum Pratense","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Depiquick Birch","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."},{"orgOrder":0,"company":"Allergopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"rBet v1-FV","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Allergopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergopharma \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Queen's University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen's University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Queen's University \/ Merck & Co"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences | Cetero Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Toleromune Hdm","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences | Cetero Research","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences | Cetero Research"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Toleromune Hdm","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"ALK","sponsor":"Inflamax Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Tree Allergen Extract","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Inflamax Research","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Inflamax Research"},{"orgOrder":0,"company":"Neuracle Science","sponsor":"Samsung Medical Center | Severance Hospital | Korea University Anam Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NS101","moa":"AMPA receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Neuracle Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuracle Science \/ Samsung Medical Center | Severance Hospital | Korea University Anam Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Neuracle Science \/ Samsung Medical Center | Severance Hospital | Korea University Anam Hospital"},{"orgOrder":0,"company":"Inotiv","sponsor":"Sea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"SPM-0404","moa":"AMPA receptor\/GRIK","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Inotiv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotiv \/ Sea Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Inotiv \/ Sea Pharmaceuticals"},{"orgOrder":0,"company":"Sea Pharmaceuticals","sponsor":"TCG Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"SPM-0404","moa":"AMPA receptor\/GRIK","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sea Pharmaceuticals \/ TCG Lifesciences","highestDevelopmentStatusID":"5","companyTruncated":"Sea Pharmaceuticals \/ TCG Lifesciences"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grunenthal \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Otonomy"},{"orgOrder":0,"company":"Otic Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ISRAEL","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otic Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Otic Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otic Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Otic Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ISRAEL","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otic Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Otic Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otic Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Exela Pharma Sciences, LLC.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Exela Pharma Sciences, LLC.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exela Pharma Sciences, LLC. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Exela Pharma Sciences, LLC. \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"Otonomy \/ ALK"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"||Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kaizen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TURKEY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cefpodoxime Proxetil","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lactic Acid","moa":"Bifunctional protein PutA; NimA-related protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Yali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Yali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MK-8237","moa":"Birch pollen allergen","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Merck & Co"},{"orgOrder":0,"company":"ALK","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MK-8237","moa":"Birch pollen allergen","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Merck & Co"},{"orgOrder":0,"company":"ALK","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MK-8237","moa":"Birch pollen allergen","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Merck & Co"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GB Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GB Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"GB Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"AM-111","moa":"c-Jun N-terminal kinase 3","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"AM-111","moa":"c-Jun N-terminal kinase 3","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BLU-808","moa":"c-Kit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"DeNova Research","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"DeNova Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"DeNova Research \/ Galderma","highestDevelopmentStatusID":"6","companyTruncated":"DeNova Research \/ Galderma"},{"orgOrder":0,"company":"Currax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Phenazon","moa":"Cyclooxygenase-1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Currax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Undisclosed"},{"orgOrder":0,"company":"Sama pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"PALESTINE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pranlukast Hydrate","moa":"CYSLTR1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sama pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Sama pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sama pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Clotrimazole","moa":"Cytochrome P450 51","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Hill Dermaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Miconazole","moa":"Cytochrome P450 51","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hill Dermaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Hill Dermaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hill Dermaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Hill Dermaceuticals, Inc.","sponsor":"Abond CRO Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Miconazole","moa":"Cytochrome P450 51","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hill Dermaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Hill Dermaceuticals, Inc. \/ Abond CRO Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Hill Dermaceuticals, Inc. \/ Abond CRO Inc."},{"orgOrder":0,"company":"Hill Dermaceuticals, Inc.","sponsor":"QST Consultations, Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Miconazole","moa":"Cytochrome P450 51","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hill Dermaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Hill Dermaceuticals, Inc. \/ QST Consultations, Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Hill Dermaceuticals, Inc. \/ QST Consultations, Ltd"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Hershey Medical Center \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Hershey Medical Center \/ Genentech"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"REGN1908","moa":"Fel d 1 (cat allergen)","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GeneOne Life Science, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"GLS-1200","moa":"Ferriprotoporphyrin IX","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"GeneOne Life Science, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GeneOne Life Science, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeneOne Life Science, Inc \/ Undisclosed"},{"orgOrder":0,"company":"D. Bradley Welling","sponsor":"Nobelpharma","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Fibroblast Growth Factor 2","moa":"FGFR1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"D. Bradley Welling","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Gel","sponsorNew":"D. Bradley Welling \/ Nobelpharma","highestDevelopmentStatusID":"7","companyTruncated":"D. Bradley Welling \/ Nobelpharma"},{"orgOrder":0,"company":"Nordmark Arzneimittel GmbH & Co. KG","sponsor":"ClinSupport | MWI Medizinisches Wirtschaftsinstitut GmbH | ProjectPharm s.r.o. | LCR Leading Clinical Research | X-act Cologne Clinical Research GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Ancrod","moa":"Fibrinogen","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Nordmark Arzneimittel GmbH & Co. KG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordmark Arzneimittel GmbH & Co. KG \/ ClinSupport | MWI Medizinisches Wirtschaftsinstitut GmbH | ProjectPharm s.r.o. | LCR Leading Clinical Research | X-act Cologne Clinical Research GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Nordmark Arzneimittel GmbH & Co. KG \/ ClinSupport | MWI Medizinisches Wirtschaftsinstitut GmbH | ProjectPharm s.r.o. | LCR Leading Clinical Research | X-act Cologne Clinical Research GmbH"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Universitas Sebelas Maret","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Universitas Sebelas Maret","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Universitas Sebelas Maret \/ Dexa Medica","highestDevelopmentStatusID":"11","companyTruncated":"Universitas Sebelas Maret \/ Dexa Medica"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fevipiprant","moa":"G protein-coupled receptor 44","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"National Institutes on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KRM-II-81","moa":"GABAA receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ National Institutes on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ National Institutes on Drug Abuse"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Contineum Therapeutics \/ Franklin Templeton","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Franklin Templeton"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Contineum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Contineum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"University of Chicago","sponsor":"MedInvent, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"University of Chicago \/ MedInvent, LLC","highestDevelopmentStatusID":"11","companyTruncated":"University of Chicago \/ MedInvent, LLC"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Cochlear","sponsor":"University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"AUSTRALIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Cochlear","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cochlear \/ University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"Cochlear \/ University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"15","companyTruncated":"KALEO INC \/ Optinose"},{"orgOrder":0,"company":"Libbs Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Libbs Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Libbs Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Libbs Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"LYR-210","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"LYR-210","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"LYR-210","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"LYR-220","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"ZonMw | Gelre Hospitals | Maasstad Hospital | Maastricht University Medical Center | Medisch Spectrum Twente | HagaZiekenhuis","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ ZonMw | Gelre Hospitals | Maasstad Hospital | Maastricht University Medical Center | Medisch Spectrum Twente | HagaZiekenhuis","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ ZonMw | Gelre Hospitals | Maasstad Hospital | Maastricht University Medical Center | Medisch Spectrum Twente | HagaZiekenhuis"},{"orgOrder":0,"company":"LifeBridge Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"LifeBridge Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Gel","sponsorNew":"LifeBridge Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LifeBridge Health \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"PH&T","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"PH&T","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PH&T \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PH&T \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Intersect ENT","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Intersect ENT \/ Medtronic Plc"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Merck & Co | Massachusetts Eye and Ear Infirmary","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Massachusetts General Hospital \/ Merck & Co | Massachusetts Eye and Ear Infirmary","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Merck & Co | Massachusetts Eye and Ear Infirmary"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Intersect ENT","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Intersect ENT \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Intersect ENT \/ Medtronic Plc"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Series C Financing","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"OPN-375","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"OTO-201","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"OTO-201","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"OTO-201","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"OTO-201","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"OTO-201","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AM-101","moa":"Glutamate [NMDA] receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AM-101","moa":"Glutamate [NMDA] receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AM-101","moa":"Glutamate [NMDA] receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AM-101","moa":"Glutamate [NMDA] receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AM-101","moa":"Glutamate [NMDA] receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Controlled Substance","year":"2022","type":"Divestment","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Undisclosed","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Undisclosed \/ Altamira Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Phafag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Caroverin","moa":"Glutamate receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Phafag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Phafag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phafag \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Selurampanel","moa":"Glutamate receptor ionotropic AMPA | Glutamate receptor ionotropic kainate","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"Glutamine","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Dalhousie University","highestDevelopmentStatusID":"6","companyTruncated":"Nova Scotia Health Authority \/ Dalhousie University"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase||Serum albumin (ALB)","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ University of Florida"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase||Serum albumin (ALB)","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase||Serum albumin (ALB)","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Med-El Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Med-El Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Med-El Corporation"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Medical University of South Carolina | Cystic Fibrosis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Medical University of South Carolina | Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Medical University of South Carolina | Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"||Glutathione synthase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ Oblato"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Carmel Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation||Xylose isomerase; Xylose isomerase; Xylose isomerase; Xylose isomerase; Hyaluronate lyase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Carmel Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Carmel Medical Center"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FX-345","moa":"GSK-3","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FX-345","moa":"GSK-3","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Shilpa Medicare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SENS-111","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Eisai","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Circassia","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"HDM-SPIRE","moa":"HDM allergens","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Quintiles Inc"},{"orgOrder":0,"company":"Azidus","sponsor":"EMS","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Azidus \/ EMS","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ EMS"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TURKEY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Epinastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Meclizine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apsen Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apsen Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acyclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"House Research Institute","sponsor":"House Clinic, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Famciclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"House Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Pill","sponsorNew":"House Research Institute \/ House Clinic, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"House Research Institute \/ House Clinic, Inc."},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"University Hospital Ghent \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Ghent \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LY3650150","moa":"IL-13 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Ivano-Frankivsk National Medical University","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UKRAINE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"BNO 1030 Extract","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Ivano-Frankivsk National Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ivano-Frankivsk National Medical University \/ Bionorica SE","highestDevelopmentStatusID":"1","companyTruncated":"Ivano-Frankivsk National Medical University \/ Bionorica SE"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BNO1016","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionorica SE \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bionorica SE \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Antwerp","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BELGIUM","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"University Hospital Antwerp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"University Hospital Antwerp \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Antwerp \/ Royal DSM"},{"orgOrder":0,"company":"A. Vogel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Echinacea Purpurea Extract","moa":"Immune system","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"A. Vogel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"A. Vogel \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"A. Vogel \/ Undisclosed"},{"orgOrder":0,"company":"XOMA","sponsor":"Germans Trias i Pujol Hospital | National Institute on Deafness and Other Communication Disorders","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Gevokizumab","moa":"Interleukin-1 beta","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XOMA \/ Germans Trias i Pujol Hospital | National Institute on Deafness and Other Communication Disorders","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Germans Trias i Pujol Hospital | National Institute on Deafness and Other Communication Disorders"},{"orgOrder":0,"company":"Stanley Cohen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Rilonacept","moa":"Interleukin-1 beta","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Stanley Cohen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stanley Cohen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Stanley Cohen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ILT-101","moa":"Interleukin-2 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Iltoo Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Virginia \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Virginia \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | ALK | Regeneron Pharmaceuticals | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | ALK | Regeneron Pharmaceuticals | PPD | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | ALK | Regeneron Pharmaceuticals | PPD | Rho, Inc"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gabrail Cancer Center Research \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Gabrail Cancer Center Research \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"CRF Health | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ CRF Health | Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ CRF Health | Bristol Myers Squibb"},{"orgOrder":0,"company":"GSK","sponsor":"Bioclinica | Signant Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Bioclinica | Signant Health","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Bioclinica | Signant Health"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Humanitas Clinical and Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Humanitas Clinical and Research Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanitas Clinical and Research Center \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Humanitas Clinical and Research Center \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acousia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acousia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"AUT00206","moa":"KV3 potassium ion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Autifony Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Autifony Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Autifony Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AUT00063","moa":"Kv7 potassium ion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Autifony Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Autifony Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autifony Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AUT00063","moa":"Kv7 potassium ion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Autifony Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Autifony Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autifony Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"University of Nottingham","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AUT00063","moa":"Kv7 potassium ion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Autifony Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autifony Therapeutics \/ University of Nottingham","highestDevelopmentStatusID":"8","companyTruncated":"Autifony Therapeutics \/ University of Nottingham"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Apslxr","moa":"Liver X receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apsen Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apsen Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Benzocaine","moa":"local anesthetics","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Arbor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Benzocaine","moa":"local anesthetics","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Arbor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stanford University \/ Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health","highestDevelopmentStatusID":"11","companyTruncated":"Stanford University \/ Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Levophencynonate HCl","moa":"Muscarinic acetylcholine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CGF166","moa":"Neurotrophic factor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Andrographolide Sulfonate","moa":"NFkB","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OTO-313","moa":"NMDA receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"OTO-313","moa":"NMDA receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AAVAnc80-hOTOF","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Novasep","sponsor":"Sensorion","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Novasep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novasep \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Novasep \/ Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Institut Pasteur","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Institut Pasteur","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Institut Pasteur"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SENS-501","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Jong Woo Chung","sponsor":"SK Chemicals | Asan Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Jong Woo Chung","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jong Woo Chung \/ SK Chemicals | Asan Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Jong Woo Chung \/ SK Chemicals | Asan Medical Center"},{"orgOrder":0,"company":"Jong Woo Chung","sponsor":"Korea Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Jong Woo Chung","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jong Woo Chung \/ Korea Otsuka Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Jong Woo Chung \/ Korea Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Series A Financing","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mercy Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercy Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercy Health \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"DB-020","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TRPharm","sponsor":"Fennec Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TURKEY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"TRPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRPharm \/ Fennec Pharma","highestDevelopmentStatusID":"1","companyTruncated":"TRPharm \/ Fennec Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kevin Winthrop","sponsor":"National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orc-13661","moa":"Potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Kevin Winthrop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kevin Winthrop \/ National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at","highestDevelopmentStatusID":"8","companyTruncated":"Kevin Winthrop \/ National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"Children's & Women's Health Centre of British Columbia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Children's & Women's Health Centre of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's & Women's Health Centre of British Columbia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Children's & Women's Health Centre of British Columbia \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ASP0598","moa":"Proheparin-binding EGF-like growth factor (HBEGF)","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Synphora AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWEDEN","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Synphora AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synphora AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synphora AB \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Actor Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH AFRICA","productType":"Dietary Supplement","year":"2023","type":"Acquisition","leadProduct":"Glycine","moa":"||quaternary ammonium derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Actor Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Gel","sponsorNew":"Actor Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Actor Pharma \/ Cipla"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Grenoble","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gadolinium","moa":"Ribonucleoside-diphosphate reductase RR1 | Thioredoxin reductase 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"University Hospital, Grenoble","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Grenoble \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Grenoble \/ GUERBET"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ACT-774312","moa":"S1P1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Creighton University School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Creighton University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creighton University School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Creighton University School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buspirone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Applied Biology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Safety Shot \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Safety Shot \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Safety Shot","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Jupiter Wellness","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Jupiter Wellness"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AK001","moa":"Siglec-8","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaceutical Project Solutions, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Pharmaceutical Project Solutions, Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmaceutical Project Solutions, Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmaceutical Project Solutions, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lannett Company, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lannett Company, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"University of Texas System | Gateway Biotechnology | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | University of Texas System | Gateway Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isosorbide","moa":"Soluble guanylate cyclase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"House Research Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"House Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"House Research Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"House Research Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Inimmune","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inimmune \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Avance Clinical"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Finafloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Finafloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Finafloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Finafloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"MerLion Pharmaceuticals","sponsor":"Fonseca Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Finafloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"MerLion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"MerLion Pharmaceuticals \/ Fonseca Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"MerLion Pharmaceuticals \/ Fonseca Biosciences"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Aav2Haqp1","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"AudioCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AC102","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AudioCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AudioCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AudioCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AudioCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AC102","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AudioCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AudioCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AudioCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Keep Hearing, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Acemg","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Keep Hearing, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Keep Hearing, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Keep Hearing, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":1.1000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Akouos","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Akouos \/ BofA Securities","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ BofA Securities"},{"orgOrder":0,"company":"Akouos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.48999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Akouos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Akouos \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"LETI Pharma","sponsor":"Laboratorios Leti | Pierrel | Labor Dr. Spranger","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Allergoid","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"LETI Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LETI Pharma \/ Laboratorios Leti | Pierrel | Labor Dr. Spranger","highestDevelopmentStatusID":"8","companyTruncated":"LETI Pharma \/ Laboratorios Leti | Pierrel | Labor Dr. Spranger"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Allergovac Depot","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Allergovac Depot","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Allergovac Depot","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Allergovac Depot","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Allergopharma","sponsor":"Inflamax Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Allergovit","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Allergopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergopharma \/ Inflamax Research","highestDevelopmentStatusID":"8","companyTruncated":"Allergopharma \/ Inflamax Research"},{"orgOrder":0,"company":"Anergis","sponsor":"Inflamax Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Allert","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Anergis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anergis \/ Inflamax Research","highestDevelopmentStatusID":"8","companyTruncated":"Anergis \/ Inflamax Research"},{"orgOrder":0,"company":"Montefiore Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Amoxicillin Clavulanate","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Montefiore Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montefiore Medical Center \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Montefiore Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Elizabeth J Franzmann","sponsor":"Aveta Biomics","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APG-157","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Elizabeth J Franzmann","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elizabeth J Franzmann \/ Aveta Biomics","highestDevelopmentStatusID":"8","companyTruncated":"Elizabeth J Franzmann \/ Aveta Biomics"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arthrospira maxima","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed"},{"orgOrder":0,"company":"Auregen Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AUR-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Auregen Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Auregen Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Auregen Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Auregen Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AUR-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Auregen Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Auregen Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Auregen Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Auregen Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AUR-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Auregen Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Auregen Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Auregen Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"3DBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Aurinovo","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"3DBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"3DBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"3DBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Autologous Fibroblast","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Castle Creek Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Castle Creek Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aryn Knight","sponsor":"Cord Blood Registry | University of Texas Health Science Center at Houston | MD Anderson Cancer Center | Baylor College of Medicine | The Methodist Hospital Research Institute | Florida Hospital for Children","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Autologous Human Umbilical Cord Blood","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Aryn Knight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aryn Knight \/ Cord Blood Registry | University of Texas Health Science Center at Houston | MD Anderson Cancer Center | Baylor College of Medicine | The Methodist Hospital Research Institute | Florida Hospital for Children","highestDevelopmentStatusID":"6","companyTruncated":"Aryn Knight \/ Cord Blood Registry | University of Texas Health Science Center at Houston | MD Anderson Cancer Center | Baylor College of Medicine | The Methodist Hospital Research Institute | Florida Hospital for Children"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"California Institute for Regenerative Medicine (CIRM) | Cook MyoSite","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Muscle Derived Stem Cell","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ California Institute for Regenerative Medicine (CIRM) | Cook MyoSite","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Davis \/ California Institute for Regenerative Medicine (CIRM) | Cook MyoSite"},{"orgOrder":0,"company":"Peter Belafsky, MD","sponsor":"Cook MyoSite","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Autologous Muscle Derived Stem Cell","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Peter Belafsky, MD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peter Belafsky, MD \/ Cook MyoSite","highestDevelopmentStatusID":"6","companyTruncated":"Peter Belafsky, MD \/ Cook MyoSite"},{"orgOrder":0,"company":"James Baumgartner","sponsor":"CBR Systems","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous Stem Cell","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"James Baumgartner","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"James Baumgartner \/ CBR Systems","highestDevelopmentStatusID":"7","companyTruncated":"James Baumgartner \/ CBR Systems"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Barium Sulfate","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Probiotics International Ltd.","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Biokult","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Probiotics International Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probiotics International Ltd. \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Probiotics International Ltd. \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BWV-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Blue Water Vaccines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Blue Water Vaccines \/ Undisclosed"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"BWV-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Blue Water Vaccines \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Blue Water Vaccines \/ St. Jude Children\u2019s Research Hospital"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Carbon Dioxide","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Circassia","sponsor":"Syneos Health | Pharm-Olam","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Syneos Health | Pharm-Olam","highestDevelopmentStatusID":"10","companyTruncated":"Circassia \/ Syneos Health | Pharm-Olam"},{"orgOrder":0,"company":"Circassia","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Circassia \/ Syneos Health"},{"orgOrder":0,"company":"Cilcare","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"CIL001","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Cilcare","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Cilcare \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Cilcare \/ Shionogi"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CKD-342","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CM9241GRU","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Creatine Monohydrate","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Powder","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"CryJ2-DNA-LAMP Plasmid Vaccine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"CryJ2-DNA-LAMP Plasmid Vaccine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Db-Oto","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DF277","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DF289","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DF289","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DF289","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"EXE844","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"EXE844","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"EXE844","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FGF-2","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"G238","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"Allergopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Grass Pollen Allergen","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Allergopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergopharma \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Grazax","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HCP1102","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HG205","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HuidaGene Therapeutics \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene Therapeutics \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HL151","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HL151","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HL151","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"House Dust Mite","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Otologic Pharmaceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"HPN-07","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Otologic Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otologic Pharmaceutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Otologic Pharmaceutics \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Iddsi Nutritional Supplement","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"INO-3106","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ University of Pennsylvania"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"Biomedical Development","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei GMNL-32","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GenMont Biotech Incorporation \/ Biomedical Development","highestDevelopmentStatusID":"10","companyTruncated":"GenMont Biotech Incorporation \/ Biomedical Development"},{"orgOrder":0,"company":"ProbiSearch SL","sponsor":"Casen Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lactobacillus salivarius PS7","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"ProbiSearch SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProbiSearch SL \/ Casen Recordati","highestDevelopmentStatusID":"1","companyTruncated":"ProbiSearch SL \/ Casen Recordati"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Lertal","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"Audion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY3056480","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Audion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Audion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Audion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Radiation Therapy Oncology Group","sponsor":"National Cancer Institute | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Manuka Honey","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Radiation Therapy Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology"},{"orgOrder":0,"company":"Alvogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Meniace","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alvogen \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Moxidex","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Myrtelle","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Partnership","leadProduct":"Myr-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Forge Biologics \/ Myrtelle","highestDevelopmentStatusID":"5","companyTruncated":"Forge Biologics \/ Myrtelle"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Toronto Sunnybrook Regional Cancer Centre | London Regional Cancer Program","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunnybrook Health Sciences Centre \/ Toronto Sunnybrook Regional Cancer Centre | London Regional Cancer Program","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Toronto Sunnybrook Regional Cancer Centre | London Regional Cancer Program"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naridrin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Sestre Milosrdnice","sponsor":"JGL d.d","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CROATIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nasal Irrigation With Seawater Isotonic Solution","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"University Hospital Sestre Milosrdnice","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"University Hospital Sestre Milosrdnice \/ Jadran Galenski laboratorij","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Sestre Milosrdnice \/ Jadran Galenski laboratorij"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Delix Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Wroclaw Medical University","sponsor":"ALL-MED Medical Research Institute, Wroclaw, Poland | Allergopharma","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"POLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Novohelisen","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Wroclaw Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wroclaw Medical University \/ ALL-MED Medical Research Institute, Wroclaw, Poland | Allergopharma","highestDevelopmentStatusID":"11","companyTruncated":"Wroclaw Medical University \/ ALL-MED Medical Research Institute, Wroclaw, Poland | Allergopharma"},{"orgOrder":0,"company":"Sonova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NR_4","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Sonova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonova \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sonova \/ Undisclosed"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OP0201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novus Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"OP0201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novus Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Ergomed | ACM Global Laboratories | Brecon Pharmaceuticals Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Osiris Phleum Pratense","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Ergomed | ACM Global Laboratories | Brecon Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Ergomed | ACM Global Laboratories | Brecon Pharmaceuticals Ltd"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"King's College London","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Otic Neural Progenitor","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ King's College London","highestDevelopmentStatusID":"7","companyTruncated":"Rinri Therapeutics \/ King's College London"},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"OTO-6XX","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OTO-825","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Florida \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Florida \/ Decibel Therapeutics"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series D Financing","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"DBTX","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ DBTX","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ DBTX"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalent Pharma Solutions \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Decibel Therapeutics"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Barclays","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Otovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OTOV101N","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Otovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Otovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pediatrica S.r.l","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Pediafl\u00f9","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Pediatrica S.r.l","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pediatrica S.r.l \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Pediatrica S.r.l \/ Tigermed"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"University of Aarhus | ALK | Lundbeck Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Phleum Pratense","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aarhus University Hospital \/ University of Aarhus | ALK | Lundbeck Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Aarhus University Hospital \/ University of Aarhus | ALK | Lundbeck Foundation"},{"orgOrder":0,"company":"CEN Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Plant Extract","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"CEN Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEN Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CEN Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Simbec Research","sponsor":"Sensorion","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SENS-218","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Simbec Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Simbec Research \/ Sensorion","highestDevelopmentStatusID":"6","companyTruncated":"Simbec Research \/ Sensorion"},{"orgOrder":0,"company":"Ruth Tachezy, PhD.","sponsor":"Medical Healthcom Prague | Na Homolce Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Silgard","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Ruth Tachezy, PhD.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruth Tachezy, PhD. \/ Medical Healthcom Prague | Na Homolce Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Ruth Tachezy, PhD. \/ Medical Healthcom Prague | Na Homolce Hospital"},{"orgOrder":0,"company":"Spiral Therapeutics","sponsor":"Savoir Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"SPT-2101","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Spiral Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Spiral Therapeutics \/ Savoir Capital","highestDevelopmentStatusID":"6","companyTruncated":"Spiral Therapeutics \/ Savoir Capital"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Staloral Birch 300 IR","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Strekin AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"STR001-IT","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Strekin AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strekin AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Strekin AG \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae Vaccine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude Children \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Thickenup Gel Express","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Tianji Jishi Biotechnology","sponsor":"PhecdaMed | Yilai Shu","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TJ0113","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Hangzhou Tianji Jishi Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hangzhou Tianji Jishi Biotechnology \/ PhecdaMed | Yilai Shu","highestDevelopmentStatusID":"1","companyTruncated":"Hangzhou Tianji Jishi Biotechnology \/ PhecdaMed | Yilai Shu"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQC2731","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQH2722","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Tusker Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Tube Placement","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Tusker Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tusker Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tusker Medical \/ Undisclosed"},{"orgOrder":0,"company":"Tusker Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Tymbion Iontophoresis And Tube Delivery System","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Tusker Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Tusker Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tusker Medical \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"V0251","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"V114","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"RUSSIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vespireit","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"WAL801CL","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Heyu Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HY01","moa":"Unknown","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Heyu Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heyu Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Heyu Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"London Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at Houston \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Texas Health Science Center at Houston \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Children's Healthcare of Atlanta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gabapentin","moa":"Voltage-gated calcium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Children's Healthcare of Atlanta","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Healthcare of Atlanta \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Children's Healthcare of Atlanta \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery Platform","graph3":"Rznomics","amount2":1.3,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Otolaryngology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Rznomics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Rznomics \/ Eli Lilly"},{"orgOrder":0,"company":"Hospital de Matar\u00f3","sponsor":"Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Hospital de Matar\u00f3","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de Matar\u00f3 \/ Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"Hospital de Matar\u00f3 \/ Nutricia Inc"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Mogrify \/ Astellas Pharma"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Aksaray University Training and Research Hospital","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TURKEY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Aksaray University Training and Research Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aksaray University Training and Research Hospital \/ World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Aksaray University Training and Research Hospital \/ World Health Organization"},{"orgOrder":0,"company":"Autigen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Autigen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autigen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Autigen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Pill","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"NMIN","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ASEP Medical \/ NMIN","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medical \/ NMIN"},{"orgOrder":0,"company":"Arrevus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ Undisclosed"},{"orgOrder":0,"company":"Mytos","sponsor":"Rinri Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"Rincell-1","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Mytos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Mytos \/ Rinri Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Mytos \/ Rinri Therapeutics"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"HONG KONG","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"HONG KONG","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Pazufloxacin Mesylate","moa":"DNA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"HONG KONG","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Pazufloxacin Mesylate","moa":"DNA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Winclove Probiotics Amsterdam","sponsor":"Alyatec","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"NETHERLANDS","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lactobacillus Strain","moa":"Microbiome","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Winclove Probiotics Amsterdam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Winclove Probiotics Amsterdam \/ Alyatec","highestDevelopmentStatusID":"1","companyTruncated":"Winclove Probiotics Amsterdam \/ Alyatec"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DW1807","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HTMC0658","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. \/ Undisclosed"}]

    Find Clinical Drug Pipelines for Otolaryngology (Ear, Nose, Throat)

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

                            Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Allergic Fungal Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 24, 2020

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved FDF

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi Receives Health Canada Approval for Dupixent to Treat Severe Chronic Rhinosinusitis with Nasal Polyposi...

                            Details : Health Canada approved a new indication for Dupixent, as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroid...

                            Product Name : Dupixent

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 18, 2020

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved FDF

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novasep

                            Germany
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Preclinical

                            Sponsor : Sensorion

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sensorion and Novasep Sign Agreement

                            Details : The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.

                            Product Name : OTOF-GT

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 11, 2020

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Preclinical

                            Sponsor : Sensorion

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Axplora Novasep

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

                            Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nasal Polyps.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 12, 2013

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Fexofenadine Hydrochloride

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (...

                            Details : Fexofenadine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Rhinitis, Allergic, Perennial.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 19, 2010

                            Lead Product(s) : Fexofenadine Hydrochloride

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Winclove Probiotics Amsterdam

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed

                            Winclove Probiotics Amsterdam

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Strain

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Undisclosed

                            Sponsor : Alyatec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis

                            Details : Lactobacillus Strain is a Probiotic drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Rhinitis, Allergic, Perennial.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : Lactobacillus Strain

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Undisclosed

                            Sponsor : Alyatec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mytos

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Mytos

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rincell-1

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Rinri Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Mytos Announces Strategic Partnerships with Rinri Therapeutics

                            Details : Rinri will look to incorporate Mytos’ automation to support the production of their otic neural progenitor cell therapy, Rincell-1 for sensorineural hearing loss.

                            Product Name : Rincell-1

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 03, 2025

                            Lead Product(s) : Rincell-1

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Rinri Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hangzhou Tianji Jishi Biotechnology

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Hangzhou Tianji Jishi Biotechnology

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TJ0113

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Undisclosed

                            Sponsor : PhecdaMed | Yilai Shu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TJ0113 Capsules Studied For Safety & Efficacy In Age-Related Hearing Loss

                            Details : TJ0113 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Presbycusis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 10, 2025

                            Lead Product(s) : TJ0113

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Undisclosed

                            Sponsor : PhecdaMed | Yilai Shu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cyrano Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Cyrano Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cyrano Completes Enrollment in Phase 2 FLAVOR Trial for Smell Loss

                            Details : CYR-064 (theophylline) is a patent-protected, intranasal formulation of a broad-spectrum PDE inhibitor designed to enhance olfactory neuron excitability and restore the sense of smell.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sensorion

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Sensorion

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Azasetron Besylate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial

                            Details : SENS-401 (R-azasetron besylate) is a 5-HT3 receptor antagonist, orally available small molecule, which is under clinical development for the treatment of Cisplatin-Induced Ototoxicity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : R-Azasetron Besylate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth